Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Return on Equity (2019 - 2025)

Historic Return on Equity for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to 0.63%.

  • Whitehawk Therapeutics' Return on Equity rose 2100.0% to 0.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.63%, marking a year-over-year increase of 2100.0%. This contributed to the annual value of 0.81% for FY2024, which is 3100.0% down from last year.
  • Whitehawk Therapeutics' Return on Equity amounted to 0.63% in Q3 2025, which was up 2100.0% from 0.5% recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Return on Equity registered a high of 0.02% during Q1 2021, and its lowest value of 1.16% during Q2 2022.
  • For the 5-year period, Whitehawk Therapeutics' Return on Equity averaged around 0.61%, with its median value being 0.59% (2023).
  • As far as peak fluctuations go, Whitehawk Therapeutics' Return on Equity plummeted by -11400bps in 2022, and later skyrocketed by 7100bps in 2023.
  • Over the past 5 years, Whitehawk Therapeutics' Return on Equity (Quarter) stood at 0.77% in 2021, then skyrocketed by 52bps to 0.37% in 2022, then plummeted by -59bps to 0.59% in 2023, then tumbled by -78bps to 1.05% in 2024, then skyrocketed by 40bps to 0.63% in 2025.
  • Its Return on Equity stands at 0.63% for Q3 2025, versus 0.5% for Q2 2025 and 0.44% for Q1 2025.